Trading Report: Today, Hologic Inc. (HOLX) VP Sold $1,258,800.00 in Stock

Today, Hologic Inc. (HOLX) VP Sold $1,258,800.00 in Stock

Hologic Inc. (NASDAQ:HOLX) VP Karleen Marie Oberton sold 31,470 shares of Hologic stock in a transaction that occurred on Monday, October 10th. The shares were sold at an average price of $40.00, for a total value of $1,258,800.00. Following the sale, the vice president now directly owns 17,005 shares in the company, valued at $680,200. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of Hologic Inc. (NASDAQ:HOLX) opened at 38.45 on Monday. Hologic Inc. has a 52 week low of $31.84 and a 52 week high of $41.66. The stock has a market capitalization of $10.67 billion, a price-to-earnings ratio of 42.39 and a beta of 1.00. The firm’s 50-day moving average is $38.49 and its 200-day moving average is $36.36.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, July 27th. The company reported $0.51 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.48 by $0.03. The company had revenue of $717.40 million for the quarter, compared to analyst estimates of $703.66 million. Hologic had a net margin of 9.39% and a return on equity of 26.25%. Hologic’s revenue was up 3.4% compared to the same quarter last year. During the same period last year, the company posted $0.43 earnings per share. Analysts forecast that Hologic Inc. will post $1.94 earnings per share for the current fiscal year.

A number of analysts have recently commented on the company. Evercore ISI reissued a “buy” rating and issued a $43.00 price target on shares of Hologic in a research report on Saturday. Leerink Swann reissued an “outperform” rating and issued a $46.00 price target on shares of Hologic in a research report on Monday, October 3rd. Zacks Investment Research raised Hologic from a “hold” rating to a “buy” rating and set a $43.00 price target on the stock in a research report on Wednesday, September 28th. Barclays PLC raised Hologic from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $42.00 to $44.00 in a research report on Friday, September 23rd. Finally, Piper Jaffray Cos. set a $44.00 price target on Hologic and gave the stock a “hold” rating in a research report on Sunday, August 28th. Six analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $42.76.

Institutional investors have recently modified their holdings of the stock. Panagora Asset Management Inc. raised its position in shares of Hologic by 247.3% in the first quarter. Panagora Asset Management Inc. now owns 1,682,853 shares of the company’s stock valued at $58,058,000 after buying an additional 1,198,338 shares during the last quarter. AMP Capital Investors Ltd raised its position in shares of Hologic by 33.8% in the first quarter. AMP Capital Investors Ltd now owns 222,865 shares of the company’s stock valued at $7,690,000 after buying an additional 56,357 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in shares of Hologic during the first quarter valued at about $689,000. Oakbrook Investments LLC acquired a new position in shares of Hologic during the second quarter valued at about $907,000. Finally, Geode Capital Management LLC raised its position in shares of Hologic by 54.3% in the first quarter. Geode Capital Management LLC now owns 2,328,326 shares of the company’s stock valued at $80,187,000 after buying an additional 819,646 shares during the last quarter. 94.49% of the stock is currently owned by institutional investors.

About Hologic

Related posts

Leave a Comment